drugset
drugset / Trial / NCT05646758

A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects

NCT05646758 ↗

Phase 1 Unknown 140 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

TQB2934 is an anti-CD3(Early T Cell Marker)×BCMA (B cell maturation antigen) double-specific antibody，and the isoform is IgG1 (Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.TQB2934 for injection is planned for the treatment of patients with multiple myeloma.

Timeline

Start
2023-03-17
Primary completion
2024-10
Completion
2025-10

Drugs

EvaluationDrugModalityDoseRoute
Subject TQB2934 Monoclonal antibody 0.09 mg Intravenous
Subject TQB2934 Monoclonal antibody 0.36 mg Intravenous
Subject TQB2934 Monoclonal antibody 1 mg Intravenous
Subject TQB2934 Monoclonal antibody 2 mg Intravenous
Subject TQB2934 Monoclonal antibody 3 mg Intravenous
Subject TQB2934 Monoclonal antibody 5 mg Intravenous
Subject TQB2934 Monoclonal antibody 6 mg Intravenous
Subject TQB2934 Monoclonal antibody 10 mg Intravenous
Subject TQB2934 Monoclonal antibody 12 mg Intravenous
Subject TQB2934 Monoclonal antibody 16 mg Intravenous
Subject TQB2934 Monoclonal antibody 20 mg Intravenous

Indications

plasma cell myeloma